The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Pancreatic Cancer Precision Medicine Market Between 2026 And 2030?
The pancreatic cancer precision medicine market size has expanded rapidly in recent years. It is forecast to grow from $0.58 billion in 2025 to $0.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.7%. The market’s historical growth can be ascribed to poor survival rates with conventional therapies, advancements in cancer genomics, an increased incidence of pancreatic cancer, expanded oncology research funding, and the early success of targeted therapies.
The pancreatic cancer precision medicine market is expected to demonstrate rapid growth in the coming years, with projections indicating it will reach $1.24 billion by 2030, expanding at a compound annual growth rate (CAGR) of 16.6%. This anticipated growth is primarily driven by the increasing adoption of precision oncology, rising investments in pancreatic cancer research, continuous advancements in diagnostic technologies, the broadening scope of immunotherapy pipelines, and the expanded utilization of companion diagnostics. Throughout the forecast period, major trends will encompass the increasing application of genomic and molecular profiling, the growing uptake of biomarker-based therapies, the expansion of combined targeted and immunotherapy treatments, the rising adoption of liquid biopsy diagnostics, and a heightened focus on personalized treatment pathways.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24354&type=smp
What Drivers Are Influencing The Pancreatic Cancer Precision Medicine Market?
The increasing occurrence of pancreatic cancer is projected to fuel the expansion of the pancreatic cancer precision medicine market in the future. Pancreatic cancer is a malignancy originating in the tissues of the pancreas, an organ vital for processes like digestion and maintaining blood sugar levels. The incidence of pancreatic cancer is escalating, attributed to a demographic shift towards an older population and the increased prevalence of associated risk factors including obesity, diabetes, and smoking. Pancreatic cancer precision medicine improves cancer management through the provision of tailored treatment strategies derived from genetic and molecular data. This approach boosts treatment efficacy and diminishes adverse reactions, establishing it as an indispensable method for more effective pancreatic cancer management. As an illustration, in February 2025, Cancer Australia, an Australian government body, reported 4,641 new cases of pancreatic cancer in 2024, comprising 2,414 males and 2,227 females. This represented a rise from 3,968 cases recorded in 2023. Consequently, the growing prevalence of pancreatic cancer is a key factor propelling the expansion of the pancreatic cancer precision medicine market.
Which Market Segments Are Examined In The Pancreatic Cancer Precision Medicine Market Study?
The pancreatic cancer precision medicine market covered in this report is segmented –
1) By Therapeutic Approach: Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approaches
2) By Diagnostic Technology: Genomic Testing, Molecular Diagnostics, Liquid Biopsy, Biomarker-Based Companion Diagnostics, Other Diagnostic Technologies
3) By Application: Hospitals, Specialty Clinics, Academic And Research Institutes, Diagnostic Centers
Subsegments:
1) By Targeted Therapy: Kinase Inhibitors, PARP Inhibitors
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy
3) By Chemotherapy-Precision Combinations: Gemcitabine-Based Combinations, Fluorouracil-Based Combinations, Nab-Paclitaxel-Based Combinations
4) By Other Therapeutic Approaches: RNA-Based Therapies, Epigenetic Modulators, Antibody-Drug Conjugates (ADCs)
Which Trends Are Influencing The Pancreatic Cancer Precision Medicine Market?
Major companies operating in the pancreatic cancer precision medicine market are concentrating on advancing technologies, such as precision medical tools, to improve early detection, facilitate accurate tumor profiling, and refine personalized treatment strategies for better patient outcomes. A precision medical tool represents a specialized device designed to accurately diagnose and treat illnesses by considering an individual’s unique biological makeup. For instance, in January 2024, Cedars-Sinai, a US-based hospital and healthcare provider, introduced its molecular twin precision oncology platform, a precision medical tool aimed at improving predictions for pancreatic cancer survival through the identification of key biomarkers. This platform demonstrates significant promise in guiding treatment decisions, even in regions with limited resources, by utilizing blood and tissue samples from 74 patients diagnosed with pancreatic ductal adenocarcinoma to deliver a more precise and accessible method for precision oncology.
Who Are The Primary Competitors In The Pancreatic Cancer Precision Medicine Market?
Major companies operating in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Amgen Inc., Eli Lilly and Company, Genentech Inc., Ipsen Pharma, Bayer AG, Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health, Foundation Medicine Inc., Oncolytics Biotech Inc., Erytech Pharma, PharmaCyte Biotech Inc., Celgene Corporation, Natera Inc.
Read the full pancreatic cancer precision medicine market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Pancreatic Cancer Precision Medicine Market?
North America was the largest region in the pancreatic cancer precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pancreatic Cancer Precision Medicine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24354&type=smp
Browse Through More Reports Similar to the Global Pancreatic Cancer Precision Medicine Market 2026, By The Business Research Company
Pancreatic Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Pancreatic Cancer Diagnostic Market Report 2026
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report
Invasive Ductal Carcinoma Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model